Insilico Medicine, an artificial intelligence (AI)-driven drug discovery company based in Hong Kong, has announced a multi-year, multi-target strategic research collaboration with French pharmaceutical major Sanofi. The partnership aims to leverage Insilico Medicine’s AI platform, Pharma.AI, to advance drug development candidates for up to six new targets.
Collaboration Details
Under the agreement, Sanofi will pay Insilico Medicine a total of up to USD 21.5 million, covering upfront and target nomination fees. This investment grants Sanofi access to Insilico’s end-to-end Pharma.AI platform and a team of interdisciplinary drug discovery scientists. The collaboration will focus on identifying, synthesizing, and advancing high-quality lead therapeutic compounds up to the development candidate stage. Additional payments could total up to USD 1.2 billion if key research, development, and sales milestones are met. The partnership also establishes mid-single to low double-digit tiered royalties for any products developed.
Future Prospects
This strategic collaboration underscores the growing importance of AI in drug discovery and development. By combining Insilico Medicine’s advanced AI capabilities with Sanofi’s expertise in pharmaceuticals, the partnership aims to accelerate the identification and development of innovative therapeutic candidates, potentially transforming the future of drug development.-Fineline Info & Tech
